Literature DB >> 19273318

Identification of autoantibody against beta-amyloid peptide in the serum of elderly.

Ji-Hoon Sohn1, Jung On So, Hyun Joo Hong, Jong Won Kim, Duk Ryul Na, Manho Kim, Hee Kim, Eunjoo Nam, Hee Jin Ha, Young Ho Kim, Inhee Mook-Jung.   

Abstract

Alzheimer's disease (AD) is characterized by two major neurological features: amyloid deposits and neurofibrillary tangles in the brain. According to the amyloid cascade hypothesis, accumulation of amyloid-beta peptide (A-beta) plays a central role in the pathogenesis of AD. Several lines of evidence suggest that antibodies against A-beta play a protective role in the neuropathology of AD. In this study, we describe the purification of an autoantibody against A-beta from human serum using affinity purification method. The purified autoantibody recognized A-beta deposits in the brain of aged Tg2676 mice, an animal model of AD. The serum levels of anti-A-beta autoantibody correlated inversely with age in both AD patients and control non-demented elderly subjects. Furthermore, the levels were significantly lower in AD patients compared with the age-matched control subjects. It is the first time to show the identification of endogenous anti-A-beta autoantibody in human serum and suggesting that serum levels of anti-A-beta autoantibody might be a good biomarker for AD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273318     DOI: 10.2741/3496

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  10 in total

1.  Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms.

Authors:  William D Brubaker; Andrés Crane; Jenny U Johansson; Kevin Yen; Kristina Garfinkel; Diego Mastroeni; Priya Asok; Bonnie Bradt; Marwan Sabbagh; Tanya L Wallace; Courtney Glavis-Bloom; Andrea J Tenner; Joseph Rogers
Journal:  Alzheimers Dement       Date:  2017-05-02       Impact factor: 21.566

2.  Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.

Authors:  Bao-Xi Qu; Yunhua Gong; Carol Moore; Min Fu; Dwight C German; Ling-Yu Chang; Roger Rosenberg; Ramon Diaz-Arrastia
Journal:  J Neuroimmunol       Date:  2014-06-27       Impact factor: 3.478

Review 3.  Microglia activation and anti-inflammatory regulation in Alzheimer's disease.

Authors:  Lih-Fen Lue; Yu-Min Kuo; Thomas Beach; Douglas G Walker
Journal:  Mol Neurobiol       Date:  2010-03-03       Impact factor: 5.590

Review 4.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

5.  ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Authors:  Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler
Journal:  J Neuroinflammation       Date:  2011-08-09       Impact factor: 8.322

6.  The Fox and the Rabbits-Environmental Variables and Population Genetics (1) Replication Problems in Association Studies and the Untapped Power of GWAS (2) Vitamin A Deficiency, Herpes Simplex Reactivation and Other Causes of Alzheimer's Disease.

Authors:  C J Carter
Journal:  ISRN Neurol       Date:  2011-07-12

7.  Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System.

Authors:  Chris Carter
Journal:  Int J Alzheimers Dis       Date:  2011-12-29

8.  Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.

Authors:  Sofia Söllvander; Frida Ekholm-Pettersson; Rose-Marie Brundin; Gabriel Westman; Lena Kilander; Staffan Paulie; Lars Lannfelt; Dag Sehlin
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 9.  Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases.

Authors:  Gabriela Kocurova; Jan Ricny; Saak V Ovsepian
Journal:  Theranostics       Date:  2022-03-28       Impact factor: 11.600

10.  Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer's Disease.

Authors:  Chris J Carter
Journal:  J Alzheimers Dis Rep       Date:  2017-09-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.